Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • EU regulator...

    EU regulator recommends suspending 300 drugs tested by Indian CRO firm

    Written by supriya kashyap kashyap Published On 2017-03-28T11:17:30+05:30  |  Updated On 28 March 2017 11:17 AM IST
    EU regulator recommends suspending 300 drugs tested by Indian CRO firm

    New Delhi : The European drug regulator has recommended suspension of around 300 medicines on which bio equivalence studies were conducted by Chennai-based Micro Therapeutic Research Labs, citing unreliability of data.


    bioequivalence studies are usually the basis for approval of generic medicines.


    The European Medicines Agency (EMA) said that the suspension has been ordered for all drugs for which the bioequivalence studies were conducted by Micro Therapeutic Research Labs at two sites in India.


    “The review, by EMA’s Committee for Medicinal Products for Human Use (CHMP), concluded that data from studies conducted at the (two) sites between June 2012 and June 2016 are unreliable and cannot be accepted as a basis for marketing authorisation in the EU,” EMA said in a statement.


    It, however, said there is no evidence of harm or lack of effectiveness of medicines authorised and being evaluated in the EU on the basis of studies at the sites.


    Aurobindo Pharma, Zydus, Sandoz, Sanofi and Mylan are among the major pharmaceutical firms that will be affected by the suspension.


    Micro Therapeutic Research Labs is a contract research organisation (CRO) which conducts analytical and clinical parts of bioequivalence studies, some of which are used to support marketing authorisation applications of medicines in the EU, it added.


    Comment from Micro Therapeutic Research Labs could not be obtained.


    The regulator also recommended that medicines not yet authorised but which are being evaluated on the basis of studies from the two sites should not be authorised until bioequivalence is demonstrated using alternative data.


    The review of medicines studied by Micro Therapeutic Research Labs was started after inspections to check compliance with good clinical practice by Austrian and Dutch authorities in February 2016, EMA said.


    “The inspections identified several concerns at the company’s sites regarding misrepresentation of study data and deficiencies in documentation and data handling,” it added.


    “The CHMP’s recommendation concerning these medicines will now be sent to the European Commission for a legally binding decision valid throughout the EU”, EMA said.


    The regulator, however, said that some of the medicines which have been recommended for suspension may be of critical importance in certain EU member states. Therefore, national authorities can temporarily postpone the suspension in the interest of patients.


    “Member States should also decide whether recalls of the affected medicines are needed in their territories,” EMA said.

    Aurobindocontract research organisationCROEuropean drug regulatorIndian CRO firmMedicinal Products for Human UseMicro Therapeutic Research Labs
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok